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Abstract
Background: The objective of this study was to examine the relationship between common genetic variation of
the ESR2 gene and osteoarthritis.
Methods: In the discovery study, the Rotterdam Study-I, 7 single nucleotide polymorphisms (SNPs) were
genotyped and tested for association with hip (284 cases, 2772 controls), knee (665 cases, 2075 controls), and hand
OA (874 cases, 2184 controls) using an additive model. In the replication stage one SNP (rs1256031) was tested in
an additional 2080 hip, 1318 knee and 557 hand OA cases and 4001, 2631 and 1699 controls respectively. Fixed-
and random-effects meta-analyses were performed over the complete dataset including 2364 hip, 1983 knee and
1431 hand OA cases and approximately 6000 controls.
Results: The C allele of rs1256031 was associated with a 36% increased odds of hip OA in women of the Rotterdam
Study-I (OR 1.36, 95% CI 1.08-1.70, p = 0.009). Haplotype analysis and analysis of knee- and hand OA did not give
additional information. With the replication studies, the meta-analysis did not show a significant effect of this SNP on
hip OA in the total population (OR 1.06, 95% CI 0.99-1.15, p = 0.10). Stratification according to gender did not change
the results. In this study, we had 80% power to detect an odds ratio of at least 1.14 for hip OA (a = 0.05).
Conclusion: This study showed that common genetic variation in the ESR2 gene is not likely to influence the risk
of osteoarthritis with effects smaller than a 13% increase.
Background
Epidemiological observations show sex-specific differ-
ences in the prevalence and incidence of osteoarthritis
(OA) [1]: the prevalence of OA among women increases
rapidly after the menopause. In addition, men have a
higher prevalence of OA before the age of 50 compared
to women. This has led to the hypothesis that sex hor-
mones may be involved in the etiology of osteoarthritis
[2]. Estrogen receptors a and ß are present in chondro-
cytes [3] and several in vitro and in vivo animal experi-
ments showed a chondro-protective effect of estrogens
[4,5]. The estrogen receptors a (ESR1 gene) and b
(ESR2 gene) are nuclear proteins. Both function as
ligand-regulated transcription factors and show tissue
specific expression.
Previously, three studies (in total 577 cases and 1837
controls) reported an association between two Single
Nucleotide Polymorphisms (SNPs) (rs2234693 and
rs9340799) of the ESR1 gene and radiographic knee and
generalized OA [6-8]. However, currently, only one
small study (158 cases, 193 controls) investigated the
role of variation in the ESR2 gene in relation to OA. A
4.5-fold increased risk of knee OA was observed in indi-
viduals carrying long alleles of the c.1092+3607(CA)n
repeat polymorphism of the ESR2 gene [9].
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any medium, provided the original work is properly cited.In this study, we examined the relationship between
common genetic variation of the ESR2 gene and radio-
graphic hip-, knee- and hand osteoarthritis in a large
population-based cohort study (the Rotterdam Study-I).
For replication purposes, 6 additional studies were geno-
typed for common genetic variation in the ESR2 gene
and a meta-analysis was performed combining all 7 stu-
dies with in total 2364 hip-, 1983 knee-, and 1431 hand
OA cases and respectively 6773, 4706 and 3883 controls.
Methods
Selection of study populations
We searched PubMed to identify articles which could be
included on this meta-analysis on common genetic var-
iation in the ESR2 gene and OA. One study [9] per-
formed an association study on common genetic
v a r i a t i o ni nt h eE S R 2g e n ea n dO Ai nC a u c a s i a n s ,b u t
this variant was not of interest to our study. Therefore,
only novel, and therefore unbiased data, is included in
this meta-analysis. Study populations with both DNA
a n da tl e a s th i pO Ad a t aa v a i l a b l ew e r ea p p r o a c h e dt o
join this meta-analysis.
Study populations
A detailed description of all studies is described in the
supplementary material (see additional file 1). In short,
the discovery study is the Rotterdam Study-I, a prospec-
tive population-based cohort which comprises men and
women aged 55 years and older [10]. The medical ethics
committee of Erasmus University Medical School
approved the study and written informed consent was
obtained from each participant. The Chingford Study is
another population-based longitudinal cohort, which
includes 1,003 women derived from the age/sex register
of a large general practice (n >11,000) in North London
[11]. The Guy’sS t .T h o m a s ’ Trust and the Waltham
Forest Trust ethics committees approved the study pro-
tocol of the Chingford Study. The Genetics osteoARthri-
tis and Progression (GARP) study, consists of Caucasian
sibling pairs and trios of Dutch origin affected by
osteoarthritis at multiple sites [12]. Written informed
consent was obtained from each subject involved in the
GARP study as approved by the ethical committees of
the Leiden University Medical Center. The Oxford TJR
sample comprises subjects ascertained using the criteria
of signs and symptoms of OA sufficiently severe to
require joint replacement surgery in the United King-
dom [13]. Ethical approval for the Oxford collection was
obtained from the Oxfordshire Clinical Research Ethics
Committee, MREC 02/2/108, with each participant pro-
viding informed consent for their sample to be used in
OA genetics studies. Greek OA cases are TJR patients
and all are individuals of Greek origin living in the dis-
trict of Thessalia in central Greece [9]. This study was
approved by the ethics committee of the Larissa Univer-
sity Hospital and all individuals gave their informed
consent. The Spanish OA cases are patients undergoing
TKR/THR and were followed in the Rheumatology Unit
[14]. This study was approved by the Ethical Committee
for Clinical Research of Galicia and all cases and con-
trols gave their written informed consent to participate.
The Study of Osteoporotic Fractures (SOF) is a multi-
center cohort study initiated in 1986 to determine risk
factors for osteoporotic fractures in elderly women [15].
The SOF study was approved by the institutional review
boards at each of the institutions involved. All subjects
provided written informed consent at enrollment and at
each clinical examination.
Osteoarthritis
In studies with radiographic OA (ROA), radiographs
were scored for the presence of ROA of the hip and
knee according to the Kellgren/Lawrence (K/L) score
[16]. Hip ROA was defined as at least definite JSN and a
definite osteophyte and knee ROA was defined as at
least 2 definite osteophytes and possible joint space nar-
rowing. Hand OA was defined as presence of at least
one definite osteophyte in 2 out of 3 hand joint groups
(DIPs, PIPs, CMC1/TS) of each or both hands. Clinical
studies defined hip-, hand- and/or knee- clinical OA
(COA) as symptomatic OA (i.e., pain and ROA) or a
TJR, which is described in the supplementary material
for each study individually. In addition, one study
(GARP) selected cases on the basis of both clinical and
radiographic OA (CROA) at two or more joint sites
among hand, spine (cervical or lumbar), knee or hip.
Genotyping
Genomic DNA was extracted from peripheral blood
leukocytes according to standard procedures. In the
Rotterdam Study, we genotyped seven tagging SNPs
(tSNPs): rs3020450, rs1256031, rs1256044, rs1256061,
rs1109056, rs1256064 and rs4986938 (tSNP1 until
tSNP7 respectively). These SNPs were selected using
the program Tagger, with force include of rs1256031
and rs4986938, incorporated in Haploview. 80% of all
common genetic variation in the ESR2 gene is covered
by these 7 SNPs. In Additional file 2: Figure S1 the
genetic variation in the ESR2 gene is depicted together
with the D’and r
2 values for the 7 SNPs. We used geno-
type data of each of the 7 SNPs to infer frequency of the
haplotype alleles using the program PHASE version 2.1
[17]. Haplotypes with an estimated probability < 95%
were excluded from analysis (387 individuals = 5.9%).
The rs1256031 SNP was genotyped for the replication
studies using a Taqman allelic discrimination assay
(Chingford Study, SOF, GARP Study, Oxford Study,
Greek cases and Spanish cases) (assay-on-demand
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spectrometry (homogeneous Mass ARRAY system;
Sequenom Inc., San Diego, CA), using standard condi-
tions with genotypes analyzed by Genotyper 3.0 soft-
ware (Sequenom Inc.)
Quality control
The allele and genotype frequencies for rs1256064
deviated slightly from HWE proportions in the Rotter-
dam Study (p = 0.04), all other SNPs were in HWE pro-
portions (data not shown). Genotyping was repeated for
a random selection of subjects (5%) to check the accu-
racy of the genotyping. No discrepancies were detected.
In addition, the allele frequency of rs1256064 is not sig-
nificantly different from that reported in the CEU Hap-
map population. No statistically significant deviations
from HWE proportions could be detected for the
rs1256031 SNP in the replication studies.
Statistical Methods
Detailed information on the statistical methods is provided
in the supplementary material (see additional file 1). In
summary, odds ratios (ORs) with 95% confidence intervals
(CI) were estimated with logistic regression (additive
model) for all the associations between SNPs and OA phe-
notypes and were subsequently adjusted for gender, age
and BMI (if available). The meta-analysis was performed
using the program Comprehensive Meta-analysis by Bio-
stat http://www.meta-analysis.com using fixed-effects and
random-effects models. Odds ratios and 95% confidence
intervals of each study were used to estimate the overall
effect size for the association between SNP rs1256031 and
hip OA. If the heterogeneity metric I
2 exceeded 25% a ran-
dom-effects model (DerSimonian and Laird) was also used
for the analysis, otherwise only a fixed effects model
(inverse variance method) was applied. The analyses were
performed on the total population of all studies and were
subsequently stratified for gender to reveal, if any, gender-
specific associations. A p-value ≤ 0.05 was considered
statistically significant. Unless otherwise stated, SPSS
version 15.0 software (SPSS INC., Chicago, USA) was used
for all analyses.
Results
Baseline characteristics
In Table 1 the characteristics of the 7 studies are given.
In total, there were 2364 hip OA cases and 6773 con-
trols, 1983 knee OA cases and 4706 controls and 1431
hand OA cases and 3883 controls available for the
meta-analysis.
Association analyses
Previously, it has been described that there is high link-
age disequilibrium (LD) across the ESR2 region and that
even between different haplotype blocks within the
ESR2 gene there is high LD [18]. In this study we also
observed high correlations (r
2 > 0.7) between rs1256031,
rs1256044 and rs1256061 and therefore results are only
presented for rs1256031 (Additional file 2: Figure S1).
Of all 7 tSNPs tested, rs1256031 showed a significant
association with hip OA in women of the Rotterdam
Study-I. In Table 2, risk of OA by different genotypes of
rs1256031 is given for men and women of the Rotter-
dam Study-I. In the Rotterdam Study-I, an allele dose
effect was observed for the C-allele of rs1256031 with a
36% increased risk of hip OA in women (adjusted for
age and BMI: OR1.36, 95% CI 1.08-1.70, p = 0.009). In
addition, in women a trend was observed in the same
direction for hand OA (OR 1.13, 95% CI 0.97-1.30, p =
0.11). No significant associations between rs1256031
and risk of OA were observed for men of the Rotterdam
Study-I. Haplotype analysis did not add additional infor-
mation (data not shown). There were no statistical sig-
nificant associations in the Rotterdam Study-I between
common genetic variation in the ESR2 gene and OA in
a dominant or recessive model.
Replication studies were genotyped for rs1256031
since this SNP was associated with hip OA in women of
the Rotterdam Study. The allele and genotype frequen-
cies for hip OA cases and controls in each study are
presented in Table 3. The association observed with hip
OA in the Rotterdam Study was not supported by the
replication studies. Results of the meta-analysis for hip
OA are shown as a forest plot for both men and women
separately and combined in Figure 1. The replication
studies together showed an OR of 1.10 (95% CI 0.98-
1.23, p-value 0.12) in women. The meta-analysis showed
a crude OR of 1.06 (95% CI 0.99-1.15, p-value 0.09) for
hip OA, OR 1.02 (95% CI 0.94-1.10, p-value 0.62) for
knee OA and OR 1.03 (95% CI 0.94-1.15, p-value 0.44
(random-effects, I
2 = 43%)) for hand OA. Additional
adjustment for age and BMI or stratification according
to gender did not essentially change the results.
Discussion
In this study, we showed by meta-analysis of 7 studies
summarizing 2364 hip OA cases and 6773 controls,
1983 knee OA cases and 4706 controls and 1431 hand
OA cases and 3883 controls, that common genetic var-
iation in the ESR2 gene is not likely to be associated
with an increased risk of osteoarthritis.
However, we have to note that we had 80% power to
detect odds ratio’s of 1.14 and therefore we cannot
exclude that smaller effects may exist. As only novel
data was included in this meta-analysis, the risk of pub-
lication bias is eliminated by this study.
The significant association of SNP rs1256031 and hip
OA in the Rotterdam Study-I was only present in
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this SNP was associated with an increased risk of ver-
tebral and fragility fractures specifically in women [18].
It was hypothesized that significant effects are not
observed in men since elderly men have higher estradiol
levels compared to postmenopausal women. These
higher serum levels of estrogens in men may mask an
impaired ESR2 signaling caused by the genetic variation
and may also explain why we observed an association
between SNP rs1256031 of the ESR2 gene and hip OA
only in women. However, the relationship between
rs1256031 and hip OA was not supported by replication
studies. Previously, Patsopoulos et al. showed that claims
of sex-related differences in genetic association studies
are most often spurious or insufficiently documented
[19]. Also in this study, where we initially did see a sex-
specific association, replication studies could not corro-
borate this result. As the effect sizes in men and women
are similar it is unlikely that interaction is present
between the SNP and gender. This observation does not
rule out a very subtle difference in the association
between males and females and rs1256031 genotypes,
but the current study is underpowered to robustly assess
this.
The small case-control study by Fytili et al. (158 cases,
1 9 3c o n t r o l s )r e p o r t e dt h a ti ndividuals carrying long
alleles of the c.1092+3607 (CA)n repeat polymorphism
of the ESR2 gene have a 4.5-fold increased risk of knee
OA. Since this repeat polymorphism was not studied in
this meta-analysis and it is not known whether this
repeat is in LD with rs1256031 we cannot conclude that
we did or did not replicate the finding of the case-
control study of Fytili and co-workers [9].
At this moment, genome-wide association studies
(GWAS) are state-of-art studies to indentify novel genetic
loci involved in complex diseases like OA. In the genome-
wide association studies published to date, common genetic
variation in the ESR2 gene has not been found associated
with OA [20-23]. In addition, GWAS on bone-related traits
like bone mineral density (BMD) did also not observe any
genome-wide significant associations between common
genetic variation in the ESR2 gene and BMD [24-26].
Conclusion
It is not likely that there is an association between com-
mon genetic variation in the ESR2 gene and hand-, hip-
or knee OA although associations with very small effect
sizes can not be excluded.
Table 1 Baseline characteristics of all studies
Rotterdam Study-I Oxford Study SOF Study Chingford Study GARP Study Greek cases Spanish cases
N (hip OA cases/controls) 284/2772 1065/727 366/1365 247/511 107/724 49/258 246/416
N (knee OA cases/controls) 665/2075 361/727 NA 302/506 148/724 258/258 249/416
N (hand OA cases/controls) 874/2184 NA NA 99/559 244/724 NA 214/416
OA definition ROA COA ROA ROA CROA COA COA
% women 58% 55% 100% 100% 70% 71% 76%
Mean age (range) 67 (55-94) 67 (55-89) 78 (72-98) 64 (54-100) 60 (43-79) 64 (18-90) 68 (55-94)
Mean BMI (range) 26 (15-59) NA 27 (15-56) 27 (17-50) 27 (19-46) 28 (17-64) NA
NA = not applicable, ROA = radiographic OA, COA = clinical OA, CROA = clinical and radiographic OA; SOF = Study of Osteoporotic Fractures.
Table 2 Risk of OA according to rs1256031 (tSNP2) genotypes in the Rotterdam Study-I
Women Rotterdam Study-I Men Rotterdam Study-I
Phenotype Genotype Nr cases/total
1 (%) OR (95% CI)
2 p-value Nr cases/total
1 (%) OR (95% CI)
2 p-value
Hip OA TT 43/534 (8.1) 1.36 (1.08-1.70) 0.009 34/408 (8.3) 1.01 (0.77-1.33) 0.93
TC 80/861 (9.3) 58/621 (9.3)
CC 46/363 (12.7) 23/269 (8.6)
Knee OA TT 122/477 (25.6) 1.09 (0.93-1.28) 0.30 60/344 (17.4) 0.85 (0.67-1.07) 0.16
TC 272/837 (32.5) 83/503 (16.5)
CC 98/346 (28.3) 30/233 (12.9)
Hand OA TT 172/510 (33.7) 1.13 (0.97-1.30) 0.11 83/418 (19.9) 0.95 (0.78-1.15) 0.58
TC 300/836 (35.9) 134/644 (20.8)
CC 131/359 (36.5) 54/291 (18.6)
1 Number of cases/total number of subjects with radiographs scored for the presence of OA;
2additive model adjusted for age and BMI.
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Study Minor allele MAF % N TT N TC N CC
Case Control Case Control Case Control Case Control
Rotterdam Study-I C 48.6 45.5 77 865 138 1344 69 563
Chingford Study C 48.6 44.7 68 159 118 247 61 105
GARP C 48.1 45.1 28 228 55 339 24 157
Greek cases C 53.1 43.0 12 83 22 128 15 47
Oxford Study C 45.6 45.7 321 224 517 342 227 161
SOF C 43.0 44.8 114 416 189 675 63 274
Spanish cases C 46.5 44.7 73 137 117 186 56 93
MAF = minor allele frequency; N = number of subjects
Figure 1 Forest plot for the association of rs1256031 (tSNP2) with hip OA adjusted for age and BMI (allelic model).F o rt h eO x f o r d
Study and Spanish cases crude odds ratio’s are shown since data on BMI and/or age was not available for the majority of subjects.
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Additional file 1: Description of study populations and statistical
methods.
Additional file 2: Figure S1: The ESR2 gene Linkage Disequilibrium
(D’) and correlation (R
2) between the tagging SNPs. Each box in the
table represents D’or R
2 for the two SNPs indicated.
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